Board of Scientific Counselors, Office of Infectious Diseases (BSC, OID), 63926 [2011-26589]
Download as PDF
<![CDATA[
63926
Federal Register / Vol. 76, No. 199 / Friday, October 14, 2011 / Notices
epidemic, very few of the available HIVprevention interventions for African
American populations have been
designed specifically for MSM. In fact,
until very recently none of CDC’s
evidence-based, HIV-prevention
interventions had been specifically
tested for efficacy in reducing HIV
transmission among MSM of color.
Given the conspicuous absence of (1)
evidence-based HIV interventions and
(2) outcome evaluations of existing
AAMSM interventions, our
collaborative team intends to address a
glaring research gap by implementing a
best-practices model of comprehensive
program evaluation.
The purpose of this project is to test
in a real world setting the efficacy of an
HIV transmission prevention
intervention for reducing sexual risk
among African American men who have
sex with men in Los Angeles County.
The intervention is a 3-session, grouplevel intervention that will provide
participants with the information,
motivation, and skills necessary to
reduce their risk of transmitting or
acquiring HIV. The intervention will be
evaluated using baseline, 3 month and
6 month follow up questionnaires. This
project will also conduct in-depth
qualitative interviews with 36 men in
order to assess the experiences with the
intervention, elicit recommendations for
improving the intervention, and to
better understand the factors that put
young African American MSM at risk
for HIV.
CDC is requesting approval for a 3year clearance for data collection. The
data collection system involves
screenings, limited locator information,
contact information, baseline
questionnaire, client satisfaction
surveys, 3-month follow-up
questionnaire, 6-month follow-up
questionnaire, and case study
interviews. An estimated 700 men will
be screened for eligibility in order to
enroll 528 men. The baseline and follow
up questionnaires contain questions
about participants’ socio-demographic
information, health and healthcare,
sexual activity, substance use, and other
psychosocial issues. The duration of
each baseline, 3-month, and 6-month
questionnaires are estimated to be 60
minutes; the Success Case Study
interviews 90 minutes; Outreach
Recruitment Assessment 5 minutes;
limited locator information form 5
minutes; participant contact information
form 10 minutes; each client satisfaction
survey 5 minutes.
There are no costs to the respondents
other than their time. The total
estimated annual burden hours are
1662.
ESTIMATED ANNUALIZED BURDEN HOURS
Type of
respondent
Form name
Prospective Participant ....................
Prospective Participant ....................
Enrolled Participant ..........................
Enrolled Participant ..........................
Enrolled Participant ..........................
Enrolled Participant ..........................
Enrolled Participant ..........................
Enrolled Participant ..........................
Outreach Recruitment Assessment (screener) ............
Limited Locator Information ..........................................
Participant Contact Information Form ...........................
Baseline Questionnaire .................................................
Client Satisfaction Survey .............................................
3 month follow up Questionnaire ..................................
6 month follow up Questionnaire ..................................
Success Case Study Interview .....................................
Dated: October 7, 2011.
Daniel Holcomb,
Reports Clearance Officer, Centers for Disease
Control and Prevention.
[FR Doc. 2011–26603 Filed 10–13–11; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
tkelley on DSK3SPTVN1PROD with NOTICES
Board of Scientific Counselors, Office
of Infectious Diseases (BSC, OID)
In accordance with section 10(a)(2) of
the Federal Advisory Committee Act
(Pub. L. 92–463), the Centers for Disease
Control and Prevention (CDC),
announces the following meeting of the
aforementioned committee:
Time and Date: 8 a.m.–4:30 p.m.,
November 9, 2011.
Place: CDC, Global Communications
Center, 1600 Clifton Road, NE., Building 19,
Auditorium B3, Atlanta, Georgia 30333.
VerDate Mar<15>2010
17:41 Oct 13, 2011
Jkt 226001
Number of
respondents
Status: Open to the public, limited only by
the space available.
Purpose: The BSC, OID, provides advice
and guidance to the Secretary, Department of
Health and Human Services; the Director,
CDC; the Director, OID; and the Directors of
the National Center for Immunization and
Respiratory Diseases, the National Center for
Emerging and Zoonotic Infectious Diseases,
and the National Center for HIV/AIDS, Viral
Hepatitis, STD, and TB Prevention, CDC, in
the following areas: strategies, goals, and
priorities for programs; research within the
national centers; and overall strategic
direction and focus of OID and the national
centers.
Matters To Be Discussed: The meeting will
include brief updates from OID and the three
infectious disease national centers, a report
from the OID/BSC Food Safety
Modernization Act working group, and
presentation of the recently released strategic
framework for CDC’s infectious disease
programs. The main topic of the meeting will
include a focused discussion, with breakout
groups, on the changing roles and
responsibilities for public health infectious
disease laboratories and the challenges and
opportunities related to new diagnostics,
PO 00000
Frm 00026
Fmt 4703
Sfmt 4703
Number
responses per
respondent
700
700
528
528
224
420
400
36
1
1
1
1
3
1
1
1
Average
burden per
respondent
(in hours)
5/60
5/60
10/60
1
5/60
1
1
1.5
other technologic advances, and a changing
economic environment.
Agenda items are subject to change as
priorities dictate.
Contact Person for More Information:
Robin Moseley, M.A.T., Designated Federal
Officer, OID, CDC, 1600 Clifton Road, NE.,
Mailstop D10, Atlanta, Georgia 30333,
Telephone: (404) 639–4461.
The Director, Management Analysis and
Services Office has been delegated the
authority to sign Federal Register notices
pertaining to announcements of meetings and
other committee management activities, for
both the Centers for Disease Control and
Prevention, and the Agency for Toxic
Substances and Disease Registry.
Dated: October 6, 2011.
Catherine Ramadei,
Acting Director, Management Analysis and
Services Office, Centers for Disease Control
and Prevention.
[FR Doc. 2011–26589 Filed 10–13–11; 8:45 am]
BILLING CODE 4163–18–P
E:\FR\FM\14OCN1.SGM
14OCN1
]]>Agencies
[Federal Register Volume 76, Number 199 (Friday, October 14, 2011)]
[Notices]
[Page 63926]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2011-26589]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
Board of Scientific Counselors, Office of Infectious Diseases
(BSC, OID)
In accordance with section 10(a)(2) of the Federal Advisory
Committee Act (Pub. L. 92-463), the Centers for Disease Control and
Prevention (CDC), announces the following meeting of the aforementioned
committee:
Time and Date: 8 a.m.-4:30 p.m., November 9, 2011.
Place: CDC, Global Communications Center, 1600 Clifton Road,
NE., Building 19, Auditorium B3, Atlanta, Georgia 30333.
Status: Open to the public, limited only by the space available.
Purpose: The BSC, OID, provides advice and guidance to the
Secretary, Department of Health and Human Services; the Director,
CDC; the Director, OID; and the Directors of the National Center for
Immunization and Respiratory Diseases, the National Center for
Emerging and Zoonotic Infectious Diseases, and the National Center
for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, CDC, in the
following areas: strategies, goals, and priorities for programs;
research within the national centers; and overall strategic
direction and focus of OID and the national centers.
Matters To Be Discussed: The meeting will include brief updates
from OID and the three infectious disease national centers, a report
from the OID/BSC Food Safety Modernization Act working group, and
presentation of the recently released strategic framework for CDC's
infectious disease programs. The main topic of the meeting will
include a focused discussion, with breakout groups, on the changing
roles and responsibilities for public health infectious disease
laboratories and the challenges and opportunities related to new
diagnostics, other technologic advances, and a changing economic
environment.
Agenda items are subject to change as priorities dictate.
Contact Person for More Information: Robin Moseley, M.A.T.,
Designated Federal Officer, OID, CDC, 1600 Clifton Road, NE.,
Mailstop D10, Atlanta, Georgia 30333, Telephone: (404) 639-4461.
The Director, Management Analysis and Services Office has been
delegated the authority to sign Federal Register notices pertaining
to announcements of meetings and other committee management
activities, for both the Centers for Disease Control and Prevention,
and the Agency for Toxic Substances and Disease Registry.
Dated: October 6, 2011.
Catherine Ramadei,
Acting Director, Management Analysis and Services Office, Centers for
Disease Control and Prevention.
[FR Doc. 2011-26589 Filed 10-13-11; 8:45 am]
BILLING CODE 4163-18-P
